Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors arising in a wide array of anatomic locations and characterized by a myomelanocytic phenotype. PEComas which occur in non-classic anatomic distributions are known as perivascular epithelioid cell tumor-not otherwise specified (PEComa-NOS), and one of the most common primary sites for PEComa-NOS is the uterus. The risk of aggressive behavior of these tumors has been linked to a number of factors evaluable on pathologic review following initial surgical resection. We report a case of PEComa-NOS of the uterus with multiple high-risk features, including frank vascular invasion, with no evidence of recurrent disease 18 months following initial surgical resection.

**Case Report**

A 50 year old gravida 3, para 3 African-American female with a distant diagnosis of uterine fibroids presented to her local emergency department with acute worsening of chronic abdominal pain which had been present for 4-6 months. Her past medical history was otherwise unremarkable with no features suggestive of tuberous sclerosis, and initial evaluation revealed hypotension and anemia with a hematocrit of 32%. Physical exam revealed a moderately tender abdomen and unremarkable pelvic exam.

Subsequent imaging in the form of a computed tomography (CT) scan revealed a large and very vascular pelvic mass with extension into the lower and midabdomen—measuring 25 cm x 11 cm x 22 cm. Moderate intraperitoneal fluid, mesenteric fat stranding and an intraluminal filling defect of the right ovarian vein were also noted.

With a working diagnosis of bleeding uterine myomata, she was taken to the operative theater the following day. Upon opening, hemoperitoneum and a large, fungating, vascular mass arising from the uterus and adherent to the overlying omentum were noted. During the dissection of the adherent omentum from the underlying tumor, a number of markedly dilated mesenteric veins were noted, and one left parametrial vein was transected, yielding an approximately 4-5 cm worm-like mass felt to be tumor thrombus.

Pathology review of the surgical specimens revealed a multinodular 22x17x10.5 cm mass arising from the superior aspect of the uterine corpus and infiltrating the subsersa and >50% of the myometrium. On gross examination, the mass was described as having hemorrhagic, tan/yellow, softened cut surfaces with multiple finger-like projections into the myometrium (Figure 1). The parametrial soft tissue margins revealed residual disease, and both ovaries contained discrete tumor nodules.

The mass extracted from the left parametral vein was also consistent with tumor. One left pelvic lymph node was sampled without evidence of metastatic disease.

Microscopic review revealed predominantly epithelioid cells with a clear to lightly eosinophilic cytoplasm; in areas the neoplastic cells showed granular cell change. Extensive areas of hemorrhage, coagulative necrosis and prominent vascular invasion were also noted; the mitotic index was 250 high powered fields (HPF) (Figure 2).

Extensive pleomorphism and occasional giant cells were noted with some cells containing intranuclear inclusions. No spindle cells were seen and the vascular pattern was relatively inapparent. The neoplastic cells were positive for HMB-45, melan A, smooth muscle actin, desmin, and estrogen receptor, while they were negative for S100, pankeratin, inhibin alpha and tyrosinase (Figure 3). Given the myomelanocytic phenotype, a diagnosis of PEComa was made. Given the size of the primary mass and the presence of multiple high risk features as proposed by Folpe, et al.,11 (Table 1) this was felt to represent a malignant or high-risk PEComa.

The patient made a full recovery, and CT of the chest, abdomen and pelvis 5 weeks following surgery revealed a small, subsegmental pulmonary embolus (PE), multiple bilateral pulmonary nodules and the patient was noted to have a large left ovarian mass. She was referred to radiation oncology for further management.

**Introduction**

Perivascular epithelioid cell tumors (PEComas) are a collection of rare tumors arising from the uterus, and characterized by a myomelanocytic phenotype. PEComas which occur in non-classic anatomic distributions are known as perivascular epithelioid cell tumor-not otherwise specified (PEComa-NOS), and one of the most common primary sites for PEComa-NOS is the uterus. The risk of aggressive behavior of these tumors has been linked to a number of factors evaluable on pathologic review following initial surgical resection. We report a case of PEComa-NOS of the uterus with multiple high-risk features, including frank vascular invasion, with no evidence of recurrent disease 18 months following initial surgical resection.

The PEComa family of tumors is now felt to be comprised of AML, CCST, LAM and less well-characterized PEComas of a variety of other anatomic origins, for which the term perivascular epithelioid cell tumor-not otherwise specified (PEComa-NOS) has been proposed.4 Multiple case reports and case series have described PEComa-NOS in a number of diverse anatomic locations including the colon, pancreas, heart and breast.5-9 One of the most common primary sites for PEComa-NOS is the female genitourinary tract, and more specifically, the uterus,10 and patients with PEComa-NOS of the uterus have demonstrated a wide variety of clinical outcomes.

**Abstract**

Perivascular epithelioid cell tumors (PEComas) are a rare collection of tumors arising in a wide array of anatomic locations and characterized by a myomelanocytic phenotype. PEComas which occur in non-classic anatomic distributions are known as perivascular epithelioid cell tumor-not otherwise specified (PEComa-NOS), and one of the most common primary sites for PEComa-NOS is the uterus. The risk of aggressive behavior of these tumors has been linked to a number of factors evaluable on pathologic review following initial surgical resection. We report a case of PEComa-NOS of the uterus with multiple high-risk features, including frank vascular invasion, with no evidence of recurrent disease 18 months following initial surgical resection.
sub-cm pulmonary nodules and a tubular 9.0×2.4 cm mass within the right gonadal vein (Figure 4). The PE, small pulmonary nodules and likely gonadal vein thrombus all raised concern as potential sites of residual disease, so a Positron Emission Tomography/Computed Tomography (PET/CT) scan was performed. This demonstrated mild, indeterminate FDG uptake both within a mass located inside the right gonadal vein as well as in the post-operative field. No distant FDG uptake was noted. After a lengthy conversation regarding the potential utility of surgical assessment of the right gonadal vein and systemic therapy, the patient opted not to pursue further diagnostic evaluation or adjuvant therapy. She was started on systemic anticoagulation with warfarin and active surveillance was undertaken in the form of serial CT scans.

Over the course of the interim 18 months, serial CT scans have demonstrated initial shrinkage followed by complete resolution of both the right gonadal vein thrombus and the subsegmental PE. The multiple small pulmonary nodules have been unchanged on serial imaging exams and there has been no radiologic evidence of local recurrence.

Given the lack of evidence for residual or recurrent malignancy, her warfarin was discontinued after a 6 month course of therapy and she has returned to an active lifestyle without complaint.

**Discussion**

Given the rarity of PEComas and their relatively recent description, little is known in regards to risk factors for development of these tumors, epidemiologic patterns of disease or natural history following initial treatment. The bulk of what is known has been gleaned from a number of case reports and case series and thus descriptive in nature. Series consistently report a strong female predominance, with a female-male ratio as high as 9:1 noted in some case series, likely at least in part to the large number of cases originating from the female genitourinary tract. Although the median age at diagnosis is typically in middle age in most series, PEComa-NOS has been diagnosed in patients ranging from 3 to 97 years of age.

PEComas have an unpredictable biologic behavior, with some tumors being unresectable or metastatic at the time of diagnosis, a majority behaving in a benign fashion and apparently curable with surgical resection alone, and still others experiencing relapse after surgery, in some cases as long as 15 years postoperatively. In an effort to better define risk factors for aggressive behavior and relapse, Folpe, et al. proposed provisional risk stratification criteria based on a number of pathologic findings in 2005. When applying these criteria to 59 cases reported in the literature at that time, 71% (12/17) patients whose cases met the criteria for malignant disease demonstrated malignant behavior, defined as metastatic or recurrent disease. These criteria have been widely adopted in an effort to predict the natural history of these rare tumors, although they have not been validated, nor has their use been uniformly linked to recommendations for management at this point.

Given the fact that gynecologic PEComas are relatively common, a number of attempts to provide useful risk stratification criteria for this subset of patients have been undertaken over the past decade. Fadare reviewed 41 reported cases of uterine PEComas and concluded that a high mitotic rate (defined as >1/10 HPF) and presence of coagulative necrosis were the best predictors of malignant behavior in this subgroup of patients. Zekry, et al. reviewed 53 cases of gynecologic (cervical, uterine and ovarian) PEComa and focused on clinical rather than pathologic risk factors. The only significant risk factors predicting a poorer prognosis were increasing age, metastatic disease at presentation, and receipt of additional therapy (chemotherapy and/or radiation therapy) as a part of a multimodality strategy including surgical resection. The authors suggest that the association between poor prognosis and need for additional therapy is likely attributable to the fact that patients felt to be at higher risk for relapse were more likely to receive additional therapy as opposed to an intrinsic harm in undergoing such treatment.

Surgery remains the mainstay of therapy when possible in PEComas of nearly every anatomic site. Surgical resection of oligometastatic disease has also been of benefit, leading to long disease-free intervals in a number of cases of relapsed disease, especial-
ly in late relapses.\textsuperscript{14,17} Radiation therapy has been utilized in a number of cases in both the neoadjuvant and adjuvant setting, without convincing results.\textsuperscript{11,14} Cytotoxic chemotherapy has similarly been integrated into multimodality therapy, with very few confirmed responses.\textsuperscript{17,18} A newer approach utilized primarily in the setting of recurrent or metastatic disease has been targeted therapy, namely mTOR inhibition.

The rationale behind mTOR inhibitor use in these tumors lies in the fact that both classic PEComas and PEComa-NOS have been shown to frequently harbor mutations in the \textit{TSC1} and/or \textit{TSC2} genes, which regulate cell proliferation via the mTOR pathway.\textsuperscript{19,20} Initial trials of these agents in the classic PEComas (AML, LAM) has led to a number of meaningful responses,\textsuperscript{21,22} sparking interest in their use for metastatic or recurrent PEComa-NOS. A number of case reports of mTOR inhibition in PEComa-NOS have now been published, with some long term responses,\textsuperscript{16} although these responses have not been uniform.\textsuperscript{23}

In conclusion, PEComa-NOS remains a rare diagnosis with a widely variant and difficult to predict natural history. This report demonstrates that even with multiple high risk features, patients can survive without recurrence for relatively long periods, as our patient had evidence of at least 4 high risk criteria on pathologic review and is without evidence of recurrence 18 months following surgical resection. Further investigation into potential predictors of poor prognosis must be undertaken in an effort to further clarify risk of aggressive behavior in patients with this diagnosis and, eventually, to help guide management decisions. Given the often indolent biologic behavior of this disease and reports of late recurrences as long as 15 years after initial surgical resection, continued vigilance will be of utmost importance in this case, especially given the history of positive surgical margins. Surgical resection of oligometastatic disease and/or mTOR inhibition would likely be the favored interventions should recurrence be detected, based on emerging data on the role of the mTOR pathway in the pathogenesis of these tumors.

### Table 1. Proposed classification of perivascular epithelioid cell tumor (adapted from Folpe et al.\textsuperscript{11})

| High risk features | Risk category |
|--------------------|---------------|
| a) Size > 5 cm | 1) Benign |
| b) Infiltrative growth pattern | <2 high risk features and size <5 cm |
| c) High nuclear grade and cellularity | 2) Uncertain malignant potential |
| d) Mitotic rate >1/50 HPF | Size >5 cm with no other high risk features OR nuclear pleomorphism/multinucleated giant cells only |
| e) Necrosis | 3) Malignant |
| f) Vascular invasion | 2 or more high risk features |

### Figure 3. Immunohistochemistry demonstrating co-expression of melan-A (A) and smooth muscle actin (B). Immunostain for S-100 was negative (C).

### Figure 4. Postoperative imaging studies. A) Computed tomography (CT) scan of the pelvis performed 34 days post surgical resection revealing persistent right gonadal vein thrombosis (arrow); B) positron emission tomography/computed tomography performed 56 days post surgical resection demonstrating mild FDG avidity in right gonadal vein region (arrow). Adjacent FDG avidity felt to be most consistent with postoperative changes; C) CT scan 12 months following surgical resection showing complete resolution of gonadal vein thrombosis following 6 month course of anticoagulation therapy.

### References

1. Folpe AL. Neoplasms with perivascular epithelioid cell differentiation (PEComas). In: Fletcher CDM, Unni KK, Mertens F (eds). World Health Organization classification of tumours. pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002: p 221-222.
2. Bonetti F, Pea M, Martignoni G, Zamboni G. PEC and sugar. Am J Surg Pathol 1992;
1. Zamboni G, Pea M, Martignoni G, et al. Clear cell sugar tumor of the pancreas: a novel member of the family of lesions characterized by the presence of perivascular epithelioid cells. Am J Surg Pathol 1996;20:722-30.

2. Fadare O, Parkash V, Yilmaz Y, et al. Perivascular epithelioid cell tumor (PComa) of the uterus cervix associated with intraabdominal PEComatosis: a clinicopathological study with comparative genomic hybridization analysis. World J Surg Oncol 2004;2:35.

3. Baek JH, Chung MG, Jung DH, Oh JH. Perivascular epithelioid cell tumor (PComa) in the transverse colon of an adolescent: a case report. Tumori 2007;93:106-8.

4. Mollazadeh R, Moaref AR, Ghazinoor M, et al. Pericardial PEComa: echocardiographic features. Int J Cardiol 2009;132:e5-7.

5. Shin J-S, Spillane A, Wills E, Cooper WA. PEComa of the retroperitoneum. Pathology 2008;40:93-5.

6. Folpe AL, Mentzel T, Lehr H-A, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005;29:1558-75.

7. Zelek N, Rettenmaier MA, Abaid LN, et al. Clear cell myomelanocytic tumor of the falciiform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults. Am J Surg Pathol 2000;24:1239-46.

8. Yamashita K, Fletcher CDM. PEComa presenting in bone: clinicopathologic analysis of 6 cases and literature review. Am J Surg Pathol 2010;34:1622-9.

9. D’Anontio AD, Caleo A, Caleo O, et al. Monotypic epithelioid engiomyolipoma of the adrenal gland: an unusual site for a rare extrarenal tumor. Ann Diagn Pathol 2009;13:347-50.

10. Govender D, Sabaratnam RM, Essa AS. Clear cell sugar tumor of the breast: another extrapulmonary site and review of the literature. Am J Surg Pathol 2002;26:670-5.

11. Folpe Al, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005;29:1558-75.

12. Zekry N, Rettenmaier MA, Abaid LN, et al. Perivascular epithelioid cell neoplasms: a systematic review of prognostic factors. J Minim Invasive Gynecol 2009;16:527-32.

13. Folpe AL, Goodman ZD, Ishak KG, et al. Clear cell myomelanocytic tumor of the falciiform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults. Am J Surg Pathol 2000;24:1239-46.

14. Yamashita K, Fletcher CDM. PEComa presenting in bone: clinicopathologic analysis of 6 cases and literature review. Am J Surg Pathol 2010;34:1622-9.

15. Peng J, Yu B, Wang J, et al. An unresectable malignant perivascular epithelioid cell tumor resistant to multiple combined chemotherapies: a unique case report. J Pediatr Hematol Oncol 2010;32:136-8.

16. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol 2010;21:1135-37.

17. Osei DA, Alvandi F, Brooks JS, Ogilvie CM. PEComa of the Upper Extremity: A Unique Case and Description of an Initial Response to Neoadjuvant Chemotherapy. Sarcoma 2007;2007:53056.

18. Leon I-s, Lee SM. Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus. J Pediatr Hematol Oncol 2005;27:681-4.

19. Benevenuto G, Li S, Brown SJ, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000;19:6306-16.

20. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-15.

21. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomylipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-51.

22. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus for angiomylipoma in tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. N Engl J Med 2008;358:200-3.

23. Subbiah V, Trent JC, Kurzrock R. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol 2010;28:e415.